The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Official Title: A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors
Study ID: NCT04660929
Brief Summary: Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
Detailed Description: A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors Main Study - Group 1 and Group 2 all HER2 overexpressing solid tumors Intraperitoneal Substudy - HER2 overexpressing peritoneal disease 89\[Zr\] radiolabeled CT-0508 Substudy - All HER2 overexpressing solid tumors (Univ of Penn, Abramson Cancer Center only) CT-0508 Combination with Pembrolizumab Substudy - All HER2 overexpressing solid tumors
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope National Medical Center, Duarte, California, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, United States
M D Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Name: Jeanett Wetzel
Affiliation: Carisma Therapeutics
Role: STUDY_DIRECTOR